{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:25Z","timestamp":1753891885051,"version":"3.41.2"},"reference-count":46,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["175014"],"award-info":[{"award-number":["175014"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2017.00437","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T13:01:31Z","timestamp":1498827691000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target?"],"prefix":"10.3389","volume":"8","author":[{"given":"Mirjana R.","family":"Jovanovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandar","family":"Miljatovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laslo","family":"Puskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slobodan","family":"Kapor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dijana L.","family":"Puskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/jvh.12173","article-title":"The new paradigm of hepatitis C therapy: integration of oral therapies","volume":"20","author":"Afdhal","year":"2013","journal-title":"J. Viral Hepat."},{"key":"B2","first-page":"1","article-title":"Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention","volume":"52","author":"Alter","year":"2003","journal-title":"MMWR Recomm. Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jsat.2011.09.007","article-title":"Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States","volume":"42","author":"Bini","year":"2012","journal-title":"J. Subst. Abuse Treat."},{"key":"B4","unstructured":""},{"key":"B5","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1046\/j.1537-2995.1995.351196110893.x","article-title":"Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study","volume":"35","author":"Busch","year":"1995","journal-title":"Transfusion"},{"volume-title":"Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease.","year":"1998","key":"B6"},{"volume-title":"Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians.","year":"2013","key":"B7"},{"volume-title":"Rockville (MD) Comparative Effectiveness Reviews, No. 69","year":"2012","author":"Chou","key":"B8"},{"key":"B9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/jvh.12123","article-title":"Viral hepatitis and the Global Burden of Disease: a need to regroup","volume":"20","author":"Cooke","year":"2013","journal-title":"J. Viral Hepat."},{"key":"B10","first-page":"1609","article-title":"Transfusion-transmitted viral infections. Retrovirus and Viral Hepatitis Working Groups of the French Society of Blood Transfusion","volume":"335","author":"Courouc\u00e9","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/1475-6773.12094","article-title":"HIV testing in the nation's opioid treatment programs, 2005\u20132011: the role of state regulations","volume":"49","author":"D'Aunno","year":"2014","journal-title":"Health Serv. Res."},{"volume-title":"European Centre for Disease Prevention and Control","year":"2015","key":"B12"},{"volume-title":"Hepatitis C Surveillance in Europe \u2013.","year":"2013","key":"B13"},{"volume-title":"Hepatitis C among Drug Users in Europe: Epidemiology, Treatment and Prevention.","year":"2016","key":"B14"},{"key":"B15","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1128\/CVI.00265-10","article-title":"Development of a multiplex bead-based assay for detection of hepatitis C virus","volume":"18","author":"Fonseca","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/S0140-6736(16)31679-8","article-title":"Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Forouzanfar","year":"2016","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.2105\/AJPH.2012.301129","article-title":"Missed opportunities for hepatitis C testing in opioid treatment programs","volume":"103","author":"Frimpong","year":"2013","journal-title":"Am. J. Public Health"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1S","DOI":"10.1111\/j.1537-2995.2009.02279.x","article-title":"Emerging infectious disease agents and their potential threat to transfusion safety","volume":"49","author":"Gregory","year":"2009","journal-title":"Transfusion"},{"key":"B19","doi-asserted-by":"publisher","first-page":"43S","DOI":"10.1002\/hep.510260708","article-title":"Diagnostic tests for hepatitis C","volume":"26","author":"Gretch","year":"1997","journal-title":"Hepatology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/00007435-200304000-00013","article-title":"Evaluation of screening criteria to identify persons with hepatitis C virus infection among sexually transmitted disease clinic clients: results from the San Diego Viral Hepatitis Integration Project","volume":"30","author":"Gunn","year":"2003","journal-title":"Sex Transm Dis."},{"key":"B21","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1177\/003335490612100611","article-title":"Self-reported hepatitis C virus antibody status and risk behaviour in young injectors","volume":"121","author":"Hagan","year":"2006","journal-title":"Public Health Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15170","article-title":"Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV\/HIV co-infection: a systematic review and economic evaluation","volume":"15","author":"Hartwell","year":"2011","journal-title":"Health Technol. Assess."},{"volume-title":"A Projection of the Healthcare and Economic Burden in the UK RAND Europe.","year":"2013","author":"Hepatitis","key":"B23"},{"key":"B24","unstructured":"Sada\u0161nji status I tro\u0161kovi le\u010denja opioidne zavisnosti u doma\u0107em zdravstvenom sektoru197199 Jakovljevi\u0107M. Jovanovi\u0107M. Psihijatrija danas432011"},{"key":"B25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/13696998.2016.1277228","article-title":"Within the triangle of health care legacies \u2013 comparing the performance of South-Eastern European health systems","volume":"20","author":"Jakovljevic","year":"2017","journal-title":"J. Med. Econ."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fpubh.2016.00002","article-title":"Health care financing and affordability in the emerging global markets","volume":"4","author":"Jakovljevic","year":"2016","journal-title":"Front. Public Health"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e6750","DOI":"10.5812\/hepatmon.6750","article-title":"Assessment of viral genotype impact to the cost-effectiveness and overall costs of care for peg-Interferon-2\u03b1 + ribavirine treated chronic hepatitis C patients","volume":"13","author":"Jakovljevic","year":"2013","journal-title":"Hepat. Mon."},{"key":"B28","doi-asserted-by":"publisher","first-page":"20952128","DOI":"10.1016\/S.0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.3748\/wjg.v20.i11.2948","article-title":"Current testing strategies for hepatitis C virus infection in blood donors and the way forward","volume":"20","author":"Marwaha","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1017\/S0950268809990616","article-title":"Diagnosis of hepatitis C virus infection in Scotland's injecting drug user population","volume":"138","author":"McDonald","year":"2010","journal-title":"Epidemiol. Infect."},{"article-title":"\u041f\u0440\u043e\u0446\u0435\u043d\u0430 \u043f\u0440\u0435\u0432\u0430\u043b\u0435\u043d\u0446\u0435 HIV-\u0430,\u0445\u0435\u043f\u0430\u0442\u0438\u0442\u0438\u0441\u0430 \u0438 \u0441\u0438\u0444\u0438\u043b\u0438\u0441\u0430, \u0440\u0438\u0437\u0438\u0447\u043d\u043e\u0433 \u043f\u043e\u043d\u0430\u0448\u0430\u04a7\u0430 \u0438 \u03ba\u043e\u0440\u0438\u0448\u0495\u0435\u04a7\u0430 \u0443\u0441\u043b\u0443\u0433\u0430 \u0443 \u043f\u043e\u043f\u0443\u043b\u0430\u0446\u0438j\u0438 \u0438\u043dj\u0435\u03ba\u0442\u0438\u0440\u0430j\u0443\u0495\u0438\u0445 \u03ba\u043e\u0440\u0438\u0441\u043d\u0438\u03ba\u0430 \u0434\u0440\u043e\u0433\u0430 \u0443 \u0411\u0435\u043e\u0433\u0440\u0430\u0434\u0443 \u0438 \u041d\u0438\u0448\u0443. \u041c\u0438\u043d\u0438\u0441\u0442\u0430\u0440\u0441\u0442\u0432\u043e \u0437\u0434\u0440\u0430\u0432\u04a7\u0430 \u0420\u0435\u043f\u0443\u0431\u043b\u0438\u03ba\u0435 \u0421\u0440\u0431\u0438j\u0435, Beograd 314:616.9-056.83(497.11)(083.41)","year":"2010","author":"Mickovski","key":"B31"},{"key":"B32","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.dld.2015.03.019","article-title":"Seroprevalence and risk factors for hepatitis C virus infection among blood donors in Serbia: a multicentre study","volume":"47","author":"Mitrovic","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/hep.20742","article-title":"Viral and host factors in early hepatitis C virus infection","volume":"42","author":"Mosley","year":"2005","journal-title":"Hepatology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/MEG.0b013e328303e1d6","article-title":"Anti-HCV reactive blood donors: clinical and epidemiological factors associated with false-reactive results","volume":"20","author":"Narciso-Schiavon","year":"2008","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jsat.2009.12.004","article-title":"HIV testing and counselling in the nation's outpatient substance abuse treatment system, 1995\u20132005","volume":"38","author":"Pollack","year":"2010","journal-title":"J. Subst. Abuse Treat."},{"key":"B36","unstructured":"RamsayM. FloodJ. HarrisH. De AngelisD. SweetingM. HopeV. Health Protection AgencyCommissioning Template for Estimating HCV Prevalence by DAT and Numbers Eligible for Treatment2011"},{"key":"B37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-156-4-201202210-00378","article-title":"The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings","volume":"156","author":"Rein","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/add.12754","article-title":"Cost-effectiveness of rapid HCV testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs","volume":"110","author":"Schackman","year":"2015","journal-title":"Addiction"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.3748\/wjg.v13.i19.2722","article-title":"Impact of hepatitis C virus infection on lifestyle","volume":"13","author":"Scognamiglio","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"B40","unstructured":"The Global FundP. Overview of Serbia2015"},{"key":"B41","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/01.PHH.0000267684.23529.2c","article-title":"Benefits and adverse effects of hepatitis C screening: early results of a screening program","volume":"13","author":"Trepka","year":"2007","journal-title":"J. Public Health Manag. Pract."},{"key":"B42","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.drugalcdep.2009.05.022","article-title":"Risk behaviours after hepatitis C virus seroconversion in young injection drug users in San Francisco","volume":"105","author":"Tsui","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Wang","year":"","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/s2352-3018(16)30087-x","article-title":"Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980\u20132015: the Global Burden of Disease Study 2015","volume":"3","author":"Wang","year":"","journal-title":"Lancet"},{"volume-title":"Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations.","year":"2014","author":"World Health Organization","key":"B45"},{"key":"B46","unstructured":"Evaluation of a risk assessment questionnaire to assist hepatitis C screening in the general population19539 ZuureF. DavidovichU. KokG. DeplaA. C. HoebeC. van den HoekA. 20429995Euro Surveill.152010"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00437\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T00:19:10Z","timestamp":1569629950000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00437\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,30]]},"references-count":46,"alternative-id":["10.3389\/fphar.2017.00437"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2017.00437","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2017,6,30]]},"article-number":"437"}}